Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer
Jochen H LorchDana Farber Cancer institute, Boston, MA, USAAbstract: Squamous cell cancer of the head and neck (SCCHN) is a major contributor to morbidity and mortality worldwide. In recent years, inhibition of the epidermal growth factor receptor has become an established treatment strategy in SCCH...
Main Author: | Jochen H Lorch |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-11-01
|
Series: | Cancer Management and Research |
Online Access: | http://www.dovepress.com/role-of-egf-inhibitors-in-the-treatment-of-recurrent-or-metastatic-squ-a3689 |
Similar Items
-
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
by: J Greenhalgh, et al.
Published: (2009-10-01) -
Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Christian Borel, et al.
Published: (2020-09-01) -
Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
by: Ronan W. Hsieh, et al.
Published: (2021-09-01) -
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
by: Athanassios Argiris, et al.
Published: (2017-05-01) -
Single Agent Irinotecan for the Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN)
by: J Gilbert, et al.
Published: (2007-01-01)